Annals of Oncology最新文献

{"title":"Elusive biomarkers of sensitivity to combined PD1/CTLA4 blockade in metastatic castration-resistant prostate cancer.","authors":"E S Antonarakis","doi":"10.1016/j.annonc.2024.10.001","DOIUrl":"10.1016/j.annonc.2024.10.001","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":56.7,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142405945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study.","authors":"D Lorusso, N Colombo, C Dubot, M V Cáceres, K Hasegawa, R Shapira-Frommer, P Salman, E Yañez, M Gümüş, M Olivera, V Samouëlian, V Castonguay, A Arkhipov, K Li, S Toker, C Tekin, K S Tewari, B J Monk","doi":"10.1016/j.annonc.2024.10.002","DOIUrl":"10.1016/j.annonc.2024.10.002","url":null,"abstract":"<p><strong>Background: </strong>In KEYNOTE-826 (NCT03635567), pembrolizumab plus chemotherapy (±bevacizumab) significantly improved overall survival (OS) and progression-free survival (PFS) in patients with persistent, recurrent, or metastatic cervical cancer. This exploratory analysis examined outcomes in patient subgroups defined by bevacizumab use.</p><p><strong>Patients and methods: </strong>Eligible adult patients had persistent, recurrent, or metastatic squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix not previously treated with chemotherapy and not amenable to curative treatment; measurable disease per RECIST v1.1; and an Eastern Cooperative Oncology Group performance status ≤1. Patients were randomly allocated 1 : 1 to pembrolizumab 200 mg every 3 weeks or placebo for up to 35 cycles plus chemotherapy (±bevacizumab 15 mg/kg). Dual primary endpoints were OS and PFS per RECIST v1.1 by investigator assessment. Outcomes were assessed in subgroups defined by bevacizumab use. Hazard ratios (HRs) and 95% confidence intervals (CIs) were based on a stratified Cox regression model.</p><p><strong>Results: </strong>A total of 617 patients were randomly assigned [pembrolizumab arm, n = 308 (63.6% with bevacizumab); placebo arm, n = 309 (62.5% with bevacizumab)]. The most common reason for bevacizumab exclusion was medical contraindication (75.9%). Among patients who received bevacizumab, HRs (95% CIs) for PFS favored the pembrolizumab arm in the programmed cell death-ligand 1 combined positive score ≥1 [0.56 (0.43-0.73)] and all-comer [0.57 (0.45-0.73)] populations; OS results were 0.60 (0.45-0.79) and 0.61 (0.47-0.80), respectively. Among patients who did not receive bevacizumab, HRs (95% CIs) for PFS also favored the pembrolizumab arm in the programmed cell death-ligand 1 combined positive score ≥1 [0.61 (0.44-0.85)] and all-comer [0.69 (0.50-0.94)] populations; OS results were 0.61 (0.44-0.85) and 0.67 (0.49-0.91), respectively. Among patients who received bevacizumab, grade ≥3 treatment-related adverse events occurred in 74.0% of patients in the pembrolizumab arm and 66.8% in the placebo arm.</p><p><strong>Conclusion: </strong>Pembrolizumab plus chemotherapy prolonged PFS and OS and had manageable safety compared with placebo plus chemotherapy in patient subgroups defined by bevacizumab use.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":56.7,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142405946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to the Letter to the Editor 'AI-assisted personalized adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma' by Y. Shimazu.","authors":"N Fraunhoffer, P Hammel, J Iovanna, N Dusetti","doi":"10.1016/j.annonc.2024.09.016","DOIUrl":"https://doi.org/10.1016/j.annonc.2024.09.016","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":56.7,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142493468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"O9-5 Efficacy of eribulin therapy in patients with advanced adenoid cystic carcinoma receiving platinum-based chemotherapy","authors":"T. Sanomachi ,&nbsp;T. Shimoi ,&nbsp;Y. Kojima ,&nbsp;A. Kawachi ,&nbsp;H. Sumiyoshi Okuma ,&nbsp;M. Hoshino ,&nbsp;M. Ito ,&nbsp;A. Saito ,&nbsp;S. Kita ,&nbsp;A. Maejima ,&nbsp;T. Nishikawa ,&nbsp;K. Sudo ,&nbsp;T. Mori ,&nbsp;K. Yonemori","doi":"10.1016/j.annonc.2024.07.645","DOIUrl":"10.1016/j.annonc.2024.07.645","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"35 ","pages":"Page S1319"},"PeriodicalIF":56.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142526036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"O6-2 Real-world treatment patterns of patients with locally advanced squamous cell carcinoma of the head and neck in Japan","authors":"K. Nibu ,&nbsp;M. Tahara ,&nbsp;N. Yoshimi ,&nbsp;R. Argoubi ,&nbsp;V. Rascon-Velasco ,&nbsp;M. Rahshenas ,&nbsp;S. Bobiak ,&nbsp;E. Lu","doi":"10.1016/j.annonc.2024.07.641","DOIUrl":"10.1016/j.annonc.2024.07.641","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"35 ","pages":"Page S1318"},"PeriodicalIF":56.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142526217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SY27-3 The future of “telepathology” using digital innovation","authors":"A. Yoshizawa","doi":"10.1016/j.annonc.2024.07.693","DOIUrl":"10.1016/j.annonc.2024.07.693","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"35 ","pages":"Page S1298"},"PeriodicalIF":56.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142532147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EJS-2 Assessing the value of new cancer drugs for regulatory and HTA decisions – the role of ESMO-MCBS","authors":"B. Gyawali","doi":"10.1016/j.annonc.2024.07.309","DOIUrl":"10.1016/j.annonc.2024.07.309","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"35 ","pages":"Page S1277"},"PeriodicalIF":56.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142532104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PSY8-1 Disparities of cancer drug affordability according to countries, healthcare systems, and financial resources","authors":"Y. Park","doi":"10.1016/j.annonc.2024.07.360","DOIUrl":"10.1016/j.annonc.2024.07.360","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"35 ","pages":"Pages S1285-S1286"},"PeriodicalIF":56.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142532204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"O14-5 Anticoagulation for distal deep venous thrombosis in cancer patients; a post-hoc analysis from PROVE-emboli study","authors":"T. Nose ,&nbsp;Y. Imamura ,&nbsp;S. Ohata ,&nbsp;K. Mori ,&nbsp;K. Otui ,&nbsp;S. Kimbara ,&nbsp;Y. Nagatani ,&nbsp;T. Koyama ,&nbsp;Y. Funakoshi ,&nbsp;N. Kiyota ,&nbsp;H. Minami","doi":"10.1016/j.annonc.2024.07.654","DOIUrl":"10.1016/j.annonc.2024.07.654","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"35 ","pages":"Page S1323"},"PeriodicalIF":56.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142531836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"O5-2 WJOG (West Japan Oncology Group) Breast Cancer Consensus Meeting 2023","authors":"Y. Kimura ,&nbsp;R. Watanuki ,&nbsp;Y. Aoyama ,&nbsp;H. Sakai ,&nbsp;A. Shimomura ,&nbsp;J. Tsurutani ,&nbsp;S. Tokunaga ,&nbsp;T. Mukohara ,&nbsp;K. Matsumoto ,&nbsp;T. Iwasa ,&nbsp;Y. Ozaki ,&nbsp;K. Nozawa ,&nbsp;M. Terada ,&nbsp;R. Kizawa ,&nbsp;T. Takano","doi":"10.1016/j.annonc.2024.07.638","DOIUrl":"10.1016/j.annonc.2024.07.638","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"35 ","pages":"Pages S1316-S1317"},"PeriodicalIF":56.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142525929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}